Antiviral immune response after live yellow fever vaccination of a kidney transplant recipient treated with IVIG

Despite the serious risk that live yellow fever virus (YFV) vaccination poses for immunocompromised individuals, inadvertent immunization does occur (1–3). We present a case study in which we measured the antiviral immune response of a kidney transplant recipient who received intravenous immunoglobulin (IVIG) as a precautionary step to reduce the risk of vaccine-associated viscerotropic disease following YFV vaccination.